New Zealand markets open in 1 hour 4 minutes

ImmunoPrecise Antibodies Ltd. (IPA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.22-0.04 (-0.76%)
As of 11:54AM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 132.41M
Enterprise value 118.92M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.95
Price/book (mrq)2.76
Enterprise value/revenue 6.11
Enterprise value/EBITDA -6.66

Trading information

Stock price history

Beta (5Y monthly) 0.63
52-week change 3-7.65%
S&P500 52-week change 3-15.72%
52-week high 36.79
52-week low 33.51
50-day moving average 34.95
200-day moving average 34.85

Share statistics

Avg vol (3-month) 314.96k
Avg vol (10-day) 315.62k
Shares outstanding 524.94M
Implied shares outstanding 6N/A
Float 820.81M
% held by insiders 11.06%
% held by institutions 15.72%
Shares short (14 Nov 2022) 4123.89k
Short ratio (14 Nov 2022) 49.78
Short % of float (14 Nov 2022) 4N/A
Short % of shares outstanding (14 Nov 2022) 40.50%
Shares short (prior month 13 Oct 2022) 4147.81k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 322 Nov 2020
Ex-dividend date 4N/A
Last split factor 21:5
Last split date 322 Nov 2020

Financial highlights

Currency in CAD.

Fiscal year

Fiscal year ends 29 Apr 2022
Most-recent quarter (mrq)30 Jul 2022

Profitability

Profit margin -117.44%
Operating margin (ttm)-117.59%

Management effectiveness

Return on assets (ttm)-19.82%
Return on equity (ttm)-37.57%

Income statement

Revenue (ttm)19.46M
Revenue per share (ttm)0.92
Quarterly revenue growth (yoy)2.20%
Gross profit (ttm)10.77M
EBITDA -20.52M
Net income avi to common (ttm)-22.86M
Diluted EPS (ttm)-0.69
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)19.24M
Total cash per share (mrq)0.77
Total debt (mrq)1.12M
Total debt/equity (mrq)1.70
Current ratio (mrq)5.06
Book value per share (mrq)2.67

Cash flow statement

Operating cash flow (ttm)-19.27M
Levered free cash flow (ttm)-9.95M